OrbusNeich Medical Group Holdings Limited (HK:6929)
:6929
Want to see HK:6929 full AI Analyst Report?
6929 Stock Chart & Stats
HK$4.44
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$4.44
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$3.45 - HK$5.71
Previous CloseN/A
Volume48.00K
Average Volume (3M)176.23K
Market Cap
HK$3.33B
Enterprise ValueHK$210.84M
Total Cash (Recent Filing)HK$218.68M
Total Debt (Recent Filing)HK$3.91M
Price to Earnings (P/E)9.2
Beta0.59
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.7%
Share Statistics
EPS (TTM)0.05
Shares Outstanding827,968,300
10 Day Avg. Volume244,250
30 Day Avg. Volume176,233
Financial Highlights & Ratios
PEG Ratio1.57
Price to Book (P/B)0.93
Price to Sales (P/S)2.13
P/FCF Ratio333.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.30Price Target Upside19.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$197.73M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageVery low debt-to-equity (~1% or less) and a large equity base with rising assets give the company durable financial flexibility. Stable ~10% ROE and conservative capital structure support investment in R&D, regulatory filings and geographic expansion while reducing insolvency risk.
Steady Revenue Growth With High Gross MarginsMid-to-high single digit revenue growth combined with persistently high gross margins (~66%–70%) points to structural pricing power and product economics in interventional cardiology. This supports long-term profitability potential and the ability to fund product development and market expansion.
Focused Product Portfolio And Multi-channel Commercial ModelA clear focus on interventional cardiovascular devices (stents, consumables) plus a mix of direct and distributor channels provides market specialization, diversified geographic exposure and scalable go-to-market capability. This reduces single-market dependency and aids durable commercial reach.
Bears Say
Weakening Cash Conversion And Low Free Cash FlowOperating cash flow covering less than net income and materially reduced free cash flow in 2024–2025 constrain internal funding for capex, new product launches, acquisitions or higher dividends. Persistent weak cash conversion elevates refinancing and liquidity risk over the medium term.
Margin Compression Since 2023Declining operating and net margins versus the 2023 peak, with 2025 net income below 2023 despite higher revenue, suggests sustained cost pressure, pricing erosion or higher SG&A. Continued margin drift would impair return on invested capital and reduce funds for strategic initiatives.
Exposure To Procedure Volumes, Tenders And ReimbursementRevenue is structurally tied to PCI procedure demand, hospital procurement cycles, distribution discounts and reimbursement decisions. Changes in procedure volumes, budget constraints or reimbursement policies across key markets can durably depress sales and make growth lumpy and policy-sensitive.
OrbusNeich Medical Group Holdings Limited News
6929 FAQ
What was OrbusNeich Medical Group Holdings Limited’s price range in the past 12 months?
OrbusNeich Medical Group Holdings Limited lowest stock price was HK$3.45 and its highest was HK$5.71 in the past 12 months.
What is OrbusNeich Medical Group Holdings Limited’s market cap?
OrbusNeich Medical Group Holdings Limited’s market cap is HK$3.33B.
When is OrbusNeich Medical Group Holdings Limited’s upcoming earnings report date?
OrbusNeich Medical Group Holdings Limited’s upcoming earnings report date is Aug 14, 2026 which is in 84 days.
How were OrbusNeich Medical Group Holdings Limited’s earnings last quarter?
OrbusNeich Medical Group Holdings Limited released its earnings results on Mar 12, 2026. The company reported HK$0.209 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.209.
Is OrbusNeich Medical Group Holdings Limited overvalued?
According to Wall Street analysts OrbusNeich Medical Group Holdings Limited’s price is currently Undervalued.
Does OrbusNeich Medical Group Holdings Limited pay dividends?
OrbusNeich Medical Group Holdings Limited pays a Notavailable dividend of HK$0.15 which represents an annual dividend yield of 2.7%. See more information on OrbusNeich Medical Group Holdings Limited dividends here
What is OrbusNeich Medical Group Holdings Limited’s EPS estimate?
OrbusNeich Medical Group Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OrbusNeich Medical Group Holdings Limited have?
OrbusNeich Medical Group Holdings Limited has 827,968,300 shares outstanding.
What happened to OrbusNeich Medical Group Holdings Limited’s price movement after its last earnings report?
OrbusNeich Medical Group Holdings Limited reported an EPS of HK$0.209 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.099%.
Which hedge fund is a major shareholder of OrbusNeich Medical Group Holdings Limited?
Currently, no hedge funds are holding shares in HK:6929
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OrbusNeich Medical Group Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.87%
12-Months-Change
Fundamentals
Return on Equity
10.21%
Trailing 12-Months
Asset Growth
5.29%
Trailing 12-Months
Company Description
OrbusNeich Medical Group Holdings Limited
OrbusNeich Medical Group Holdings Limited, an investment holding company, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People's Republic of China, and the United States. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, coronary stents for implantation, non-compliant balloons for post-dilatation, and specialty catheters. Its product portfolio covers various treatment processes in percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. The company was founded in 2001 and is headquartered in Shatin, Hong Kong. OrbusNeich Medical Group Holdings Limited is a subsidiary of Harmony Tree Limited.
6929 Stock 12 Month Forecast
Average Price Target
HK$5.30
▲(19.37% Upside)
Technical Analysis
Shandong Weigao Group Medical Polymer Co
―
―
PW Medtech Group Ltd.
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
Angelalign Technology Inc.
―
Options Prices
Currently, No data available
---